Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

The Original Article was published on 12 August 2021

Correction to: Leukemia https://doi.org/10.1038/s41375-021-01374-3

In the original article, the publisher missed to include the final contribution statement.

Caroline Rolfes and Thomas Wiesmann contributed equally to this paper as senior authors.

The original article has been updated.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Andreas Neubauer.

Additional information

Co-last authors Caroline Rolfes, Thomas Wiesmann

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Neubauer, A., Johow, J., Mack, E. et al. Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia (2021). https://doi.org/10.1038/s41375-021-01412-0

Download citation

Search

Quick links